Another concern with targeting CD30 for CAR-T cell therapy in HL is that high concentrations of soluble CD30 have been found in patients with progressed HL, which may compete for CAR binding (Jackson et al., 2016); However, a preclinical study showed that this concern was unwarranted (Hombach et al., 1998). The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.